Melanoma | Bentham Science
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Review Article

Melanoma

Author(s): Vamsee Torri, Wojciech Dolata, Khanh Vu, Arbind Dubey, Bryan Brunet and Patricia Tai

Volume 12, Issue 3, 2016

Page: [172 - 203] Pages: 32

DOI: 10.2174/1573394713666170113115759

Price: $65

Open Access Journals Promotions 2
Abstract

Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.

Keywords: Sentinel node biopsy, systemic therapy, chemotherapy, radiotherapy, node dissection, targeted therapy, treatment, sites.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy